Mirion Technologies, Inc.

MIR
About the company

Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety.

Country: United StatesPrice: $17.74Market Cap: $4.5B

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

$6.33

-64.3% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Buffett, Lynch, Marks +1 more object

Key risk

All 13 investors flag MIR's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1569 (Top 50.7%)NEUTRALFAILFAILFAILFAILFAILFAILFAILPASSFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-321.4%-200.2%N/A-3125.5%N/AN/A-135.6%-163.2%N/AN/A-111.2%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-19

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-10-28

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-10-28

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Buffett, Lynch, Marks +1 more object

    LT Debt vs Net Current AssetsLT Debt $444.0M vs NCA $605.1M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.24, IC: 1.4x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.25
    ✓Lynch< 0.33
    Cash - Long-term Debt$-35.3M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change25.99% -> 12.35%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities3.02
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.25
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.25
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=1.4x, D/EBITDA=2.3x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.25
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.2486; #1856/4210 (top 44.1%)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow60% pass✓ 7✗ 5▾

    6 of 10 pass — Dreman, Pabrai, Ackman +1 more object

    Free Cash Flow Proxy$130.5M
    ✓BuffettPositive and growing
    FCF Positive and Growing$168.0M
    ✓LynchPositive and growing
    Operating Cash Flow$143.3M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=3.99%, ROA=0.80%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)32.3x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=161.3x, FCF Yield=2.4%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive6/7 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap3.6%
    ✗Ackman>= 4%
    Price / FCF per Share43.3x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency7/7 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$168.0M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+3.77%; #1860/4519 (top 41.2%)
    ✗OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✗ 28▾

    All 13 investors flag MIR's valuation

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio2.5x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 161.3x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value1.4%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.4%, ROC=18.2%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS161.3x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)32.3x
    ✗Dreman< 8x
    Price / Book Value per Share2.5x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=161.3x, OE Yield=2.8%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=161.3x, FCF Yield=2.4%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=161.3x, P/B=2.5x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share43.3x
    ✗Ackman<= 25
    Price vs. Trailing Low124% of trailing low ($14.34)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+0.65%; #3055/6340 (top 48.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.4007; #3280/6449 (top 50.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS161.3x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.2422; #3580/5247 (top 68.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+3.77%; #1860/4519 (top 41.2%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-7.94%; #3306/6202 (top 53.3%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 3✗ 10▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 161.3x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 8.7% vs Rev: 19.6%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/8 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth7.5%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 44.5% -> 47.4%, operating margin -2.7% -> 5.6%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR8.6%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Valuation models0% pass✗ 6▾

    MIR overvalued: all 6 models price fair value below $17.74 (median $6.33)

    Graham fair value$4.21
    ✗Graham-321.4% margin vs $17.74
    Buffett fair value$5.91
    ✗Buffett-200.2% margin vs $17.74
    Greenblatt fair value$0.55
    ✗Greenblatt-3125.5% margin vs $17.74
    Munger fair value$7.53
    ✗Munger-135.6% margin vs $17.74
    Pabrai fair value$6.74
    ✗Pabrai-163.2% margin vs $17.74
    Ackman fair value$8.40
    ✗Ackman-111.2% margin vs $17.74
  • Profitability6% pass✓ 6✗ 29▾

    15 of 16 flag MIR's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/9 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/9 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-7.3%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)5.6% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$130.5M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 161.3x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE1.6%
    ✗Lynch> 15%
    EBIT / Enterprise Value1.4%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.4%, ROC=18.2%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets0.80%
    ✓PiotroskiROA > 0
    ROA Change YoY-1.37% -> 0.80% (delta: +2.17%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=3.99%, ROA=0.80%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY46.4% -> 47.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue3.7%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity1.6%
    ✗Dreman> 12%
    Margin of SafetyP/E=161.3x, P/B=2.5x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-2.5% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/8 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue6.0%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity1.6%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-2.7% (2023) -> 5.6% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 44.5% -> 47.4%, operating margin -2.7% -> 5.6%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+0.65%; #3055/6340 (top 48.2%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+14.83%; #2436/3702 (top 65.8%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+1.62%; #2792/5226 (top 53.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0370; #2180/5884 (top 37.0%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/7 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts7% pass✓ 1✗ 14▾

    Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #1569•PiotroskiNEUTRAL (F-Score 7)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (3/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1720/2370 (Top 72.6%))✗NeffFAIL (2/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag MIR's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio3.02
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-2.2%
    ✗Buffett> 10%
    ROIC - WACC-12.2%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)18.2%
    ✗Greenblatt> 25%
    Current Ratio Change YoY2.26 -> 2.83
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.33x -> 0.26x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities3.02
    ✓Dreman> 1.5
    Return on Invested Capital2.3%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-0.8%; FY2024: ROIC=0.9%; FY2025: ROIC=1.8%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC1.8% (RR=100% x ROIC=1.8%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest 1.8%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Measuring and Control Equipment
SIC Sector: Measuring & Medical Instruments
Size: Mid Cap($4.5B)
Revenue: $925.4M+7.5% YoY
Net Income: $28.8M+179.8% YoY

Financial Snapshot

Operating Margin5.6%
Return on Equity1.5%
Debt / Equity0.24
Current Ratio2.83
EPS (Diluted)$0.11
Buybacks (1y)$49.6M
Buybacks (2y)$49.6M
Shares Retired−27.4% / −33.0% 2y

Similar Companies

TMOTHERMO FISHER SCIENTIFIC INC.
$259.4B
DHRDANAHER CORP /DE/
$163.9B
WATWATERS CORP /DE/
$90.5B
AAGILENT TECHNOLOGIES, INC.
$49.0B

Shareholder Return

Fiscal 2025

Issued 27.4% of shares last year, 33.0% issued over two.

Buybacks
$49.6M
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-19
FY 2024
Sources
  • 10-K · 2025-02-26
FY 2023
Sources
  • 10-K · 2024-02-28
FY 2022
Sources
  • 10-K · 2023-02-28
FY 2021
Sources
  • 10-K · 2022-02-28
Market Cap$4.5Bcurrent------$6.5Best.$3.2Best.$1.9Best.$1.4Best.--
Revenue$1.1B↑20%$277.8M↑25%$266.8M↑20%$257.6M↑28%$925.4M↑8%$860.8M↑7%$800.9M↑12%$717.8M--
Operating Income$64.3M↑17%$17.2M↑132%$17.9M↑81%$3.7M↓57%$51.5M↑108%$24.8M↑213%-$21.9M↑93%-$297.8M--
Net Income$29.0M↑9%$7.4M↑155%$7.7M↓7%-$3.4M↓1233%$28.8M↑180%-$36.1M↑63%-$96.9M↑65%-$276.9M↓75%-$158.4M
EPS (Diluted)--$0.03↑200%$0.03$-0.01$0.11↑161%$-0.18↑63%$-0.49↑68%$-1.53--
Gross Margin48.1%↑2%47.3%↑1%49.9%↑8%46.2%↓3%47.4%↑2%46.4%↑4%44.5%↑3%43.2%—
Operating Margin6.0%↓2%6.2%↑87%6.7%↑51%1.4%↓67%5.6%↑93%2.9%↑205%-2.7%↑93%-41.5%—
ROE1.6%↑13%———1.5%↑164%-2.4%↑63%-6.5%↑67%-19.8%↓112%-9.4%
Total Debt$444.0M$444.0M$445.3M$445.1M↓35%$444.7M↓35%$686.4M$685.9M↓15%$806.8M$810.7M
Shareholders' Equity$1.8B↓3%$1.8B↓3%$1.8B↑25%$1.8B↑22%$1.9B↑24%$1.5B↑1%$1.5B↑6%$1.4B↓17%$1.7B
Current Ratio3.02↓38%3.02↓38%3.20↑26%3.19↑43%2.83↑25%2.26↑11%2.03↑3%1.97↓4%2.05
Debt / Equity0.25↑3%0.25↑3%0.24↓20%0.24↓47%0.24↓48%0.46↓1%0.46↓20%0.58↑21%0.48
Operating Cash Flow$209.6M↑60%$59.2M↑165%$58.5M↑372%$18.9M↓47%$143.3M↑45%$99.1M↑4%$95.2M↑142%$39.4M--
Free Cash Flow$168.0M↑81%$47.3M↑264%$48.1M↑1236%$9.4M↓65%$106.9M↑113%$50.3M↓13%$58.1M↑1017%$5.2M--

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Measuring and Control Equipment

MIR vs Peers — Financial Grading

Revenue$925.4MBottom 25%
Net Income$28.8MBottom 25%
ROE1.5%Bottom 25%
D/E0.24Top 25%
Op. Margin5.6%Bottom 25%
Curr. Ratio2.83Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
THERMO FISHER SCIENTIFIC INC.TMO$259.4B$700.22$44.6B$6.7B12.6%0.7417.4%1.893/93/93/71/3F-Score 57/11
DANAHER CORP /DE/DHR$163.9B$233.02$24.6B$3.6B6.9%0.3519.1%1.873/94/92/71/3F-Score 54/11
WATERS CORP /DE/WAT$90.5B$460.25$3.2B$642.6M25.1%0.5525.4%1.731/94/91/70/3F-Score 45/11
AGILENT TECHNOLOGIES, INC.A$49.0B$173.96$6.9B$1.3B19.3%0.4521.3%1.962/95/93/71/3F-Score 55/11
ROPER TECHNOLOGIES INCROP$47.5B$479.98$7.9B$1.5B7.7%0.4728.3%0.522/93/93/70/3F-Score 64/11
COHERENT CORP.COHR$43.0B$218.15$5.8B$49.4M0.9%0.691.6%2.193/91/90/70/3F-Score 44/11
TERADYNE, INCTER$39.0B$249.55$3.2B$554.0M19.8%0.0720.4%1.752/96/94/71/3F-Score 66/11
ILLUMINA, INC.ILMN$31.3B$207.01$4.3B$850.0M31.2%0.7318.6%2.082/91/93/71/3F-Score 85/11